Анализ белков, ассоциированных с экспрессией циклооксигеназы-2 и биосинтезом PGE2 в клетках рака молочной железы с разным метастатическим потенциалом

Проведено картирование протеома лизатов линий опухолевых клеток молочной железы MCF-7, BT-474, ZR-75-1, в результате секвенировано 340 белков. Идентифицированы белки, ассоциированные с биосинтезом PGE2 и регуляцией экспрессии циклоокси- геназы-2, и определены их относительные уровни экспрессии. В данной группе особый интерес представляют потенциальные мишени для направленной терапии рака молочной железы: рецепторы простагландинов E2 , D2 , простагландин Е-синтаза, 15-гид- рокси-простагландиндегидрогеназа и лейкотриен-А4-гидролаза.

рак молочной железы, циклооксигеназа-2, рецепторы простагландинов E2 , D2 , простагландин Е-синтаза, 15-гид- рокси-простагландиндегидрогеназа, лейкотриен-А4-гидролаза, линии опухолевых клеток молочной железы человека MCF-7, BT-474, ZR-75-1, протеомика, ма

1. Parkin D.M., Ferlay J., Curado M.P. et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010;127(12):2918−27.

2. Schedin P., Borges V. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Breast Cancer Research 2009;11(2):102.

3. Cebola I., Peinado M.A. Epigenetic deregulation of the COX pathway in cancer. Prog Lipid Res 2012;51(4):301−13.

4. Шевченко В.Е. Современные масс- спектрометрические методы в ранней диагностике рака. Масс-спектрометрия 2004;1(2):103−26.

5. Шевченко В.Е., Арноцкая Н.Е., Трифонова О.П. и др. Профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака легкого. Масс-спектромет- рия 2007;4(4):245−54.

6. Pyatnitskiy M.A., Arnotskaya N.E., Akhmedov B.B. et al.Identification of differential signs of squamous cell lung carcinoma by means of the mass spectrometry profiling of blood plasma. J Analyt Chem 2011;66(14):1369−75.

7. Kang U.B., Ahn Y., Lee J.W. et al. Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. BMC Cancer 2010;10:114.

8. Sarvaiya H.A., Yoon J.H., Lazar I.M. et al. Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation. Rapid Commun Mass Spectrom 2006; 20(20):3039−55.

9. Шевченко В.Е., Ковалев С.В., Юрченко В.А. и др. Картирование протеома плазмы крови человека в норме и при светлоклеточном раке почки. Онкоурология 2011;3:65−69.

10. Шевченко В.Е., Арноцкая Н.Е., Таипов М.А. и др. Масс-спектрометрическое профилирование низкомолекулярного протеома плазмы крови для обнаружения потенциальных маркеров рака молочной железы. Вестн РОНЦ 2011;22(3):27−33.

11. Shevchenko V.E., Arnotskaya N.E., Zaridze D.G. et al. Detection of lung cancer using plasma protein profiling by matrix- assisted laser desorption/ionization mass spectrometry. Eur J Mass Spectrom 2010;16(4):539−49.

12. Шевченко В.Е., Макаров Д.Е., Ковалев С.В. и др. Идентификация протеомных маркеров метастазирования рака яичников. ОЖРС 2011;4:76−83.

13. Шевченко В.Е., Таипов М.А., Ковалев С.В. и др. Картирование протеома лизата линии опухолевых клеток MCF-7 для идентификации потенциальных маркеров рака молочной железы. ОЖРС 2012;2:4−11.

14. Kuk C., Kulasingam V., Diamandis E.P. et al. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 2009;8(4):661−9.

15. Alo P.L., Trombetta G. et al. Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 1999;85:35−40.

16. Jin Q.,Yuan L.X, Boulbes D. et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Research 2010;12(6):96.

17. Ishimura N., Amano Y., Sanchez-Siles A.A. et al. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis. J Clin Gastroenterol 2011;45(8):665−72.

18. Ogino S., Brahmandam M., Cantor M. et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Modern Pathology 2006; 19:59−68.

19. Xuan Y.T., Guo Y., Zhu Y. et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 2003;35(5):525−37.

20. Doppler W., Marth C., Daxenbichler G. et al. Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue. Breast Cancer Research 2005;7(2):4−5.

21. Amoroso M.R, Matassa D.S, Laudiero G. et al. TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death & Differentiation 2012;19:592−604.

22. Houliston R.A., Keogh R.J., Sugden D. et al. Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost 2002; 88(2):321−8.

23. Frasor J., Weaver A.E., Pradhan M. et al. Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17 beta-estradiol and proinflammatory cytokines. Endocrinology 2008;149(12):6272−9.

24. Lee J.J., Natsuizaka M., Ohashi S. et al. Hypoxia activates the cyclooxygenase-2- prostaglandin E synthase axis. Carcinogenesis 2010;31(3):427−34.

25. Simpson N.E., Lambert W.M., Watkins R. et al. High Levels of Hsp90 Cochaperone p23 Promote Tumor Progression and Poor Prognosis in Breast Cancer by Increasing Lymph Node Metastases and Drug Resistance. Cancer Research 2010;70(21):8446−56.

26. Tanioka T., Nakatani Y., Semmyo N. et al. Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2 Biosynthesis. J Biolog Chemistry 2000;275:32775−82.

27. Wood L.D., Parsons D.W., Jones S. et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108−13.

28. Wang T.H., Chao A., Tsai C.L. et al. Stress-induced phosphoprotein 1 as a Secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol cell proteomics 2010;9(9):1873−84.

29. Kang S.H., Kang K.W., Kim K.H. et al. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 2008;8:286.

30. Wolf I. O'Kelly J., Rubinek T. et al. 15-Hydroxyprostaglandin Dehydrogenase Is a Tumor Suppressor of Human Breast Cancer. Cancer Res 2006;66:7818.

31. Timoshenko A.V., Xu G., Chakrabarti S. et al. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289(2):265−74.

32. Lai T.C., Chou H.C., Chen Y.W. et al. Secretomic and proteomic analysis of potential breast cancer markers by two-dimensional differential gel Electrophoresis. J Proteome Res 2010;9(3):1302−22.

33. Chen X., Wang S., Wu N.et al. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 2004; 4(3):267−83.

34. Sun Z, Sood S., Li N. et al. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogen 2006;27(9):1902−8.

35. Ohd J.F., Wikstrom K., Sjolander A. Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterol 2000;119:1007−18.

36. Laronga C.,Yang H.Y., Neal C., Lee M.H. Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression. J Biological Chem 2000; 275:23106−12.

37. O'Regan R.M., Gajdos C., Dardes R.C. et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94(4):274−83.

38. Chen H, Liu L, Ma B. Protein kinase A-mediated 14-3-3 Association Impedes Human Dapper1 to Promote Dishevelled Degradation. J Biol Chem 2011;286: 14870−80.

39. Wu K.K, Liou J.Y. Cyclooxygenase inhibitors induce colon cancer cell apoptosis Via PPARdelta –> 14-3-3epsilon pathway. Methods Mol Biol 2009;512:295−307.

40. Niemantsverdriet M., Wagner K., Visser M. et al. Cellular functions of 14-3-3 dzeta in apoptosis and cell adhesion emphasize its oncogenic character Oncogenic properties of 14-3-3 dzeta. Oncogene 2008;27:1315−9.

41. Lu J., Guo H., Treekitkarnmongkol W. et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009;16(3):195−207.

42. Danes C.G., Wyszomierski S.L., Lu J. et al. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008;68(6):1760−7.

43. Neal C.L., Xu J., Li P. et al. Overexpression of 14-3-3 dzeta in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2012;31:897−906.

44. Qi W., Liu X., Chen W. Overexpression of 14-3-3γ causes polyploidization in H322 lung cancer cells. Molecular Carcinogenesis 2007;46(10):847−56.

45. Jin Y.H., Kim Y.J., Kim D.W. et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 2008;368:690−5.

46. Radhakrishnan V.M., Martinez J.D. 14-3-3gamma induces oncogenic transformation by stimulating MAP kinase and PI3K signaling. PLoS One 2010;5(7):11433.

47. Zhang A., Dong Z., Yang T. Prostaglandin D2 inhibits TGF-beta 1-induced epithelial- to-mesenchymal transition in MDCK cells. Am J Physiol Renal Physiol 2006;291:1332−42.

48. Murata T., Lin M.I., Aritake K. et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. PNAS 2008;105(50):20009−14.

49. Wolf I., O’Kelly J., Rubinek T. et al. 15-Hydroxyprostaglandin Dehydrogenase Is a Tumor Suppressor of Human Breast Cancer Cancer Res 2006;66:7818−23.

50. Lehtinen L., Vainio P., Wikman H. et al. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells. J Pathol 2012;226(4): 674−86.

51. Wakimoto N., Wolf I., Yin D. et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglan- din dehydrogenase. Cancer Res 2008; 68(17):6978−86.

52. Roberts H.R., Smartt H.J., Greenhough A. et al. Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the micro environmental stress of glucose deprivation. Carcinogenesis 2011; 32(11):1741−7.

53. Liu Z., Wang X., Lu Y. et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008;29(6): 1219−27.

54. Na H.K., Park J.M., Lee H.G. et al. 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol 2011;82(10):1352−60.

55. Yom C.K., Han W., Kim S.W. et al. Clinical Significance of Annexin A1 Expression in Breast Cancer. J Breast Cancer 2011;14(4):262−8.

56. Parente L, Solito E. Annexin 1: more than an anti-phospholipase protein. Inflamm Res 2004;53(4):125−32.